Compare Nasdaq100 ETF (QQQ) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq100 ETF vs Revvity Inc — how do they compare? Nasdaq100 ETF trades at $751.26 (market cap $506.92B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Nasdaq100 ETF is far larger — about 29.9× Revvity Inc's market cap, and Revvity Inc pays a 0.18% dividend while Nasdaq100 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq100 ETF for 162 Days and Revvity Inc for 12 Days on average.
| QQQ | RVTY | |
|---|---|---|
Market Cap | $506.92B | $16.98B |
Volume | 48,326,518 | 1,456,900 |
52-Week High | $759.66 | $157.36 |
52-Week Low | $558.34 | $82.26 |
Typical Hold Time | 162 Days | 12 Days |
Sector | — | Health |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $751.27, down 0.85% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF shows strong institutional interest but faces mixed analyst sentiment with a 50% buy and 50% sell rating. Recent news highlights ongoing comparisons with lower-fee alternatives like QQQM and VOO, while AI-driven tech exposure remains a key growth driver amid market volatility concerns.
The outlook for QQQ hinges on tech sector performance and interest rate sensitivity. Opportunities include AI innovation and Nasdaq 100 leadership, but risks involve high concentration in tech stocks, valuation pressures, and macroeconomic headwinds. Investor sentiment is divided, reflecting the ETF's growth potential against fee competitiveness and market cyclicality.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
